At present, there is still a lack of effective treatment drugs for AD, and modified therapies targeting the core pathological molecules of AD (Aβ and tau proteins) have shown unsatisfactory therapeutic effects in clinical trials, and the lag in the intervention time may be an important reason for the poor results of these drug trials (Toledo et al., 2011). Here, MAPT is linked to Alzheimer disease.